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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Studies conducted in Eastern Asia suggest that serum uric acid (SUA)
level is highly related to nonalcoholic fatty liver disease (NAFLD). However, limited informa-
tion is available in the USA. Our objective was to determine the association between NAFLD
and SUA levels in the USA and to determine if this is independent of age, sex, and components
of metabolic syndrome (MetS).
Methods: We analyzed 5370 men and women aged 20e74 years from the Third National Health
and Nutrition Examination Survey (NHANES III) (1988e1994) in the USA. We calculated the prev-
alence and odds ratio (OR) of NAFLD and elevated liver enzymes by SUA and sex-specific quin-
tiles of SUA, adjusting for multiple factors.
Results: The prevalence of NAFLD was higher in participants with higher SUA levels (10.9%,
9.6%, 15.9%, 21.8% and 33.1%, respectively, from the second to the fifth sex-specific quintile
of uric acid). After adjustment, individuals with hyperuricemia were more likely to have NAFLD
(OR: 1.4, 95% CI: 1.1e1.9). Similarly, the adjusted odds of NAFLD were increasingly higher from
the second to the fifth quintile of SUA (ORs: 0.8, 1.2, 1.5 and 1.7, respectively; p < 0.01) as
compared to the lowest quintile. Finally, individuals with hyperuricemia were more likely to
have elevated liver enzymes (aspartate aminotransferase or alanine aminotransferase)
(adjusted OR: 1.8, 95% CI: 1.1e2.7).onument Street, Suite 2-600, Baltimore, MD 21287, USA.
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Serum uric acid and NAFLD 315Conclusion: NAFLD and SUA levels were strongly and independently associated in this nation-
ally representative sample of men and women after adjustment for multiple factors.
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Hepatic steatosis is the accumulation of fat (usually
triglyceride) within the hepatic parenchyma. It is usually
asymptomatic, but can cause malaise, a sensation of full-
ness, or discomfort on the right side of the upper abdomen.
In the absence of significant alcohol consumption and other
causes of liver disease, hepatic steatosis is usually called
nonalcoholic fatty liver disease (NAFLD).1 The prevalence
of NAFLD exceeds 25% by ultrasound surveys of the general
population in some countries.2
NAFLD contains a range of manifestations from simple
steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, and
liver cirrhosis, which may lead to hepatocellular carcinoma
(HCC) and liver failure.1,3 Nutritional, metabolic and
genetic factors contribute to the occurrence of NAFLD.1,4,5
In addition, oxidative stress, insulin resistance and systemic
inflammation are known as important risk factors for the
development or progression of the liver diseases including
NAFLD and NASH. Recently, several observational studies
suggest that hyperuricemia (serum uric acid (SUA) level
>7.0 mg/dL in men and >5.7 mg/dL in women) is a risk
factor for NAFLD among eastern Asian populations inde-
pendent of the components of metabolic syndrome
(MetS).6e9 In fact, there is some evidence that insulin
resistance can lead to reduced excretion of SUA and
increased SUA level.10,11 However, data in the USA have
been limited to liver enzymes and advanced liver disease.12
Therefore, we hypothesized that there also exists a rela-
tionship between hyperuricemia and NAFLD among the US
population. In addition, there is a quantitative relationship
between SUA level and NAFLD.
Our primary objective was: (1) to determine the asso-
ciation between ultrasound-defined NAFLD and SUA; and (2)
to determine if hyperuricemia is associated with
ultrasound-defined NAFLD independent of well-known risk
factors. In secondary analyses we investigated the rela-
tionship between hyperuricemia and liver enzymes
including aspartate aminotransferase (AST) and alanine
aminotransferase (ALT), using data representative of the US
population.
Methods
Study population
We used data from the Third National Health and Nutrition
Examination Survey (NHANES III), which was conducted
between 1988 and 1994, and contains a representative
sample of the noninstitutionalized US civilian population.13
For our study, we initially included 6967 participants
between the ages of 20 and 74 years who were eligible for
ultrasound examination of the gallbladder14 and had
a videotape reviewed for hepatic steatosis, had fasted atleast 8 hours before the blood collection, had blood tested
for SUA and liver enzymes, had complete information for
definition of the MetS and had no other missing information.
After excluding participants who reported only excessive
alcohol consumption (n Z 467) (>2 drinks for men; >1
drink for women; 1 drink Z 14 g alcohol); who only had
serum transferrin saturation >50% (n Z 220), hepatitis B
(n Z 197) or C (n Z 88) infection; who were only taking
diuretics (n Z 367), anti-gout medicine (n Z 17), or zido-
vudine/didanosine (n Z 1); those with two or more of the
above conditions (nZ 240), we included 5370 individuals as
our analytic sample (Fig. 1).
Data collection
NHANES III collected data through interviewer question-
naires, physical examination, laboratory measurements,
and gallbladder ultrasound examination. Detailed descrip-
tion of data collection can be found elsewhere.13 Ques-
tionnaires collected sociodemographic information,
including age, sex and race/ethnicity. Race/ethnicity was
categorized into non-Hispanic white, non-Hispanic black,
Mexican American, and others. In addition, information on
alcohol consumption (frequency and amount) and medical
history (including medication use, and diagnosis of diabetes
and hypertension) was also obtained. The physical exami-
nation included measurement of height, weight, waist
circumference and systolic and diastolic blood pressure.
Body mass index (BMI) was calculated. Gallbladder ultra-
sound was performed using a Toshiba (Tustin, CA, USA) SSA-
90A machine using 3.75 and 5.0 MHz transducers. Labora-
tory measurements included SUA, plasma glucose, serum
total cholesterol, serum high-density lipoprotein choles-
terol (HDL-C), serum triglyceride (TG) and liver enzymes,
including serum AST and ALT.
All NHANES III participants aged 20e74 years who were
part of the gallbladder ultrasound examination and had the
archived ultrasound videotapes were eligible for review of
liver echo-texture between 2009 and 2010. In total, 13,856
NHANES III participants had a successful hepatic steatosis
ultrasound assessment (96.7% of all the participants with
available gallbladder data). Five criteria including liver
parenchymal brightness, liver-to-kidney contrast, deep
beam attenuation, bright vessel walls, and gallbladder wall
definition were used to determine hepatic steatosis.
Detailed description can be found elsewhere.15 Briefly, the
degree of steatosis was assessed by the following five
criteria: (1) the degree of the liver parenchymal brightness
(none/intermediate/moderate/severe); (2) the presence
of liver-to-kidney contrast (yes/no/not assessed); (3) the
presence of posterior deep bean attenuation (yes/no/not
assessed); (4) the presence of bright vessel walls (yes/no/
not assessed); (5) the definition of gallbladder (clear/
intermediate/obliterated/not assessed). According to the
five parameters, participants with steatosis were classified
Figure 1 Flowchart of selection of study population. )Excessive alcohol consumption is defined as >1 drink/day for women and
>2 drinks/day for men; 1 drink Z 14 g alcohol.
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ysis, we defined NAFLD for participants with moderate or
severe steatosis.
Hyperuricemia was defined as SUA level >7.0 mg/dL in
men and >5.7 mg/dL (to convert to micromoles per liter,
multiply by 59.48) in women according to the laboratory
reference for NHANES.16 Overweight was defined as
BMI  25 kg/m2. MetS was defined according to National
Cholesterol Education ProgrameAdult Treatment Panel III
(NCEP-ATPIII) criteria: abdominal obesity (waist circum-
ference >102 cm in men and >88 cm in women); hyper-
triglyceridemia (150 mg/dL or 1.69 mmol/L); low HDL-C
(<40 mg/dL or 1.04 mmol/L in men and <50 mg/dL or
1.29 mmol/L in women); high blood pressure (130/
85 mmHg); and high fasting glucose (100 mg/dL or
6.1 mmol/L).17 Hepatic steatosis was defined as the
presence of moderate or severe steatosis by ultrasound
regardless of the presence of other liver diseases. NAFLD
was defined as the presence of steatosis without excessive
alcohol consumption, or use of zydovudine or didanosine,
which were found to be associated with the presence of
steatosis. Finally, elevated liver enzymes were defined as
an AST level >37 U/L in men or >31 U/L in women; and an
ALT level >40 U/L in men or >31 U/L in women according to
the laboratory reference for NHANES.16 We defined unex-
plained abnormal liver enzymes as elevations in AST and/
or ALT without excessive alcohol consumption, hepatitis B
infection, hepatitis C infection, or serum transferrin satu-
ration >50%.Statistical analysis
The distribution of hepatic steatosis, NAFLD, the MetS
components, MetS, alcohol use, race/ethnicity, and
abnormal liver enzymes were compared by the presence or
absence of hyperuricemia using the c2 test. The means of
age and BMI were compared by the presence or absence ofhyperuricemia using unpaired t test. We calculated the
unadjusted, age- and sex-adjusted, and multivariable-
adjusted odds ratios of NAFLD by the presence or absence
of hyperuricemia after adjusting for age, sex, race/
ethnicity, alcohol consumption, BMI, fasting plasma
glucose, systolic pressure, serum HDL-C, and serum TG.
Likewise, the prevalence of NAFLD among the total study
population was calculated according to five sex-specific
percentiles (quintiles) of serum uric acid levels:
0.8e3.6 mg/dL, 3.7e4.2 mg/dL, 4.3e4.7 mg/dL,
4.8e5.5 mg/dL, and 5.6e10 mg/dL for women;
1.7e5.1 mg/dL, 5.2e5.7 mg/dL, 5.8e6.3 mg/dL,
6.4e7.0 mg/dL, and 7.1e11.4 mg/dL for men. We also
performed logistic regression analyses to evaluate the
association of NAFLD with SUA across quintile and calcu-
lated unadjusted odds ratio (OR), age-adjusted OR, and
multivariable-adjusted OR (same adjustment as used
for the prevalence estimates). Finally, we used logistic
regression to evaluate the association between elevated
SUA levels and abnormal liver enzymes and calculated
unadjusted, age- and sex-adjusted, and multivariable-
adjusted ORs after controlling for age, sex, race/
ethnicity, alcohol consumption, BMI, fasting plasma
glucose, systolic pressure, serum HDL-C, and serum TG.
All statistical analyses were computed using the survey
commands of Stata statistical software to incorporate
sample weights and adjust for clusters and strata of the
complex sampling design (Version 11; Stata Corporation,
College Station, TX, USA). Values were considered statisti-
cally significant if p values were less than 0.05.
Results
Clinical characteristics of study population
The characteristics of the study population are showed in
Table 1 by the presence or absence of hyperuricemia.
Table 1 Clinical characteristics of the study population with and without hyperuricemia.
Weighted prevalence Study cohort Without
hyperuricemiaa
With
hyperuricemiaa
p
Unweighted, n n Z 5370 n Z 4489 n Z 881
Mean age (y) 40.8
(40.3e41.4)
40.4 (0.31) 43.1 (0.62) 0.001
Sex
Male 47.6 46.3 54.5 0.004
Race/ethnicity
NH White 75.7 75.7 75.8 0.38
NH Black 10.3 10.1 11.8
Mexican American 5.9 6.0 5.1
Other races 8.1 8.2 7.4
Alcohol consumptionb
Never 12.9 13.2 11.2 0.22
Low 87.1 86.8 88.9
Mean BMI (kg/m2) 26.3
(26.1e26.5)
25.6
(25.4e25.8)
30.0
(29.4e30.6)
<0.001
BMI  25 kg/m2 54.4 49.2 82.3 <0.001
Waist circumference
(cm) >102 (M), >88 (W)
34.2 29.8 57.6 <0.001
BP  130/85 mmHgc 27.5 24.2 45.0 <0.001
Fasting glucose >100 mg/dLd 24.9 23.3 33.4 <0.001
HDL-C (mg/dL) <40 (M), <50 (W) 38.2 35.3 53.7 <0.001
TGs > 150 mg/dL 27.2 23.0 49.4 <0.001
MetS components 3 25.3 20.8 49.2 <0.001
Data are presented by incorporating sample weights and adjusted for clusters and strata of the complex sample design of the Third
National Health and Nutrition Examination Survey; data are expressed as means (SD range) or as percentages.
BMI Z body mass index; BP Z blood pressure; HDL-CZ high-density lipoprotein cholesterol; M Z men; MetS Z metabolic syndromes;
NH Z non-Hispanic; TGs Z triglycerides; W Z women.
a Hyperuricemia: >7 mg/dL in men; >5.7 mg/dL in women.
b Alcohol consumption: low (1 drink/day in women, 2 drinks/day in men); 1 drink Z 14 g alcohol.
c Systolic blood pressure 130 mmHg, diastolic blood pressure 85 mmHg, or patients who reported currently using antihypertensive
medications.
d Containing patients who self-reported physician diagnosis of diabetes mellitis.
Serum uric acid and NAFLD 317Overall 16.4% had hyperuricemia (unweighted). Those with
hyperuricemia were significantly older (43.1 vs. 40.4 years,
p Z 0.001), more likely to be male (54.5% vs. 46.3%,
p < 0.05), and overweight (82.3% vs. 49.2%, p < 0.001) than
those without hyperuricemia. The prevalence of each
individual MetS component was significantly higher among
individuals with hyperuricemia as was the overall preva-
lence of the MetS (49.2% vs. 20.8%, p < 0.001).
Associations between hepatic steatosis, NAFLD,
and SUA levels
As shown in Table 2, the overall prevalence of NAFLD was
17.7% [95% confidence interval (CI) 16.1e19.4%], and was
significantly higher in those with hyperuricemia compared
to those without (33.8% vs. 14.7%, p < 0.001). Individuals
with hyperuricemia were 40% more likely to have NAFLD
even after adjusting for age, sex, race/ethnicity, alcohol
consumption, BMI, fasting plasma glucose, systolic pres-
sure, serum HDL-C, and serum TG (OR 1.4, 95% CI 1.1e1.9).
Overall, the likelihood of NAFLD increased with increasing
SUA levels among total study population. As shown in Table
3, the overall prevalence of NAFLD was 10.9%, 9.6%, 15.9%,21.8% and 33.1%, respectively from the first sex-specific
quintile to the fifth. Compared to the lowest quintile, the
odds of NAFLD was 0.8, 1.2, 1.5 and 1.7 across the second
to the fifth quintile of uric acid even after adjustment for
age, race/ethnicity, alcohol consumption, and components
of the MetS (p < 0.001). Moreover, we further explored
whether there was a doseeresponse relationship between
the severity of NAFLD (none, intermediate, moderate, and
severe) and quintiles of SUA levels and found no evidence
supporting such a relationship.
Association between liver enzymes and serum uric
acid
As shown in Table 4, individuals with hyperuricemia had
a higher prevalence of elevated liver enzymes compared to
those without (AST 8.9% vs. 3.0%, p < 0.001; ALT 9.6% vs.
4.7%, p < 0.001). In addition, individuals with hyperuri-
cemia were more likely to have elevated liver enzymes (AST
or ALT), even after adjusting for age, sex, race/ethnicity,
alcohol consumption, BMI, fasting plasma glucose, systolic
pressure, serum HDL-C, and serum TG (OR 1.8, 95% CI
1.1e2.7).
Table 2 Association between nonalcoholic fatty liver disease (NAFLD) and serum uric acid (SUA) levels.
Weighted prevalence or
odds ratio (OR) (95%
confidence interval)
Study
cohort
Without
hyperuricemiaa
With
hyperuricemiaa
p
Unweighted, n n Z 5370 n Z 4489 n Z 881
NAFLDb 17.7% 14.7% 33.8% <0.001
NAFLD:
Unadjusted OR 1 3.0 (2.3e3.9) <0.001
Age- and sex-adjusted OR 1 2.8 (2.2e3.7) <0.001
Multivariable-adjusted ORc 1 1.4 (1.1e1.9) <0.01
Data are presented by incorporating sample weights and adjusted for clusters and strata of the complex sample design of the Third
National Health and Nutrition Examination Survey.
a Hyperuricemia: >7 mg/dL in men; >5.7 mg/dL in women.
b NAFLD: hepatic steatosis without excessive alcohol consumption, or use of zydovudine or didanosine.
c Adjusted for age, sex, race/ethnicity, alcohol consumption, body mass index, (systolic) blood pressure, fasting glucose, high-density
lipoprotein cholesterol and triglycerides.
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In this nationally representative sample of men and women,
we found that individuals with hyperuricemia had a higher
prevalence of NAFLD and, furthermore, that there was
a doseeresponse relationship between SUA level and
NAFLD. Hyperuricemia was associated with NAFLD inde-
pendent of age, sex, race/ethnicity, alcohol, BMI, and all
components of the MetS. In addition, individuals with
hyperuricemia are more likely to have elevated liver
enzymes (AST or ALT) even after adjustment.
Our findings confirm those of previous studies in eastern
Asia (i.e., elevated SUA levels significantly contributed to
the risk for NAFLD among patients who participated in
health check-ups).6e9 In addition, our results extend
previous findings from the NHANES which relied on elevated
liver enzymes only.12 The associations are robust and occur
in a nationally representative sample of the US population
for two manifestations of NAFLD: (1) hepatic steatosis; and
(2) elevated liver enzymes (AST or ALT), and amongTable 3 Prevalence and odds ratio (OR) of NAFLD according to
Weighted prevalence
and OR
Serum uric aci
Quintile 1 Quintile 2 Q
Unweighted,
n (total n Z 5370)
n Z 1166 n Z 1136 n
NAFLDb 10.9% 9.6% 1
Unadjusted OR (95%
confidence interval, CI)
1 0.9 (0.6e1.4) 1
Age-adjusted OR (95% CI) 1 0.9 (0.6e1.4) 1
Multivariable-adjusted
OR (95% CI)c
1 0.8 (0.5e1.4) 1
Data are presented by incorporating sample weights and adjusted fo
National Health and Nutrition Examination Survey.
a Serum uric acid level (mg/dL) quintiles: for women 0.8e3.6, 3.7
5.8e6.3, 6.4e7.0 and 7.1e11.4.
b NAFLD: hepatic steatosis without excessive alcohol consumption,
c Adjusted for age, sex, race/ethnicity, alcohol consumption, body m
lipoprotein cholesterol and triglycerides.different subgroups (by sex, age, and race/ethnicity) as
well as the entire population.
The development of NAFLD is complex and still not well
understood. Many factors, including genetic, metabolic,
and dietary risk factors, are postulated to contribute to the
development of NAFLD.4 Mechanistically, NAFLD is thought
to represent the results of two distinct steps of hepatic
insults (the “two-hit” theory of NAFLD). The first “hit” is
the development of hepatic steatosis caused by an imbal-
ance of hepatic lipid metabolism; and the second “hit” is
a concurrent inflammatory process potentially resulting
from oxidative stress, peroxidation, and cytokines actions.4
Uric acid is produced as the end-product of purine break-
down. People generally acquire purine from increased
intake of purine-rich foods (such as meats and seafood),
monosaccharide fructose, and alcohol.18 As for fructose,
once it enters into hepatocytes, it is rapidly phosphorylated
and intracellular phosphate levels fall, which triggers the
activity of adenosine mono-phosphate (AMP) deaminase.
Finally, AMP deaminase results in substrate-dependentsex-specific quintiles of serum uric acid.
d levels (mg/dL) by quintilea p for
trenduintile 3 Quintile 4 Quintile 5
Z 994 n Z 1083 n Z 991
5.9% 21.8% 33.1%
.5 (1.0e2.3) 2.3 (1.6e3.3) 4.0 (2.8e5.8) <0.001
.5 (1.0e2.3) 2.3 (1.6e3.3) 3.8 (2.7e5.5) <0.001
.2 (0.8e1.9) 1.5 (1.0e2.2) 1.7 (1.1e2.5) <0.001
r clusters and strata of the complex sample design of the Third
e4.2, 4.3e4.7, 4.8e5.5 and 5.6e10; for men 1.7e5.1, 5.2e5.7,
or use of zydovudine or didanosine.
ass index, (systolic) blood pressure, fasting glucose, high-density
Table 4 Association between liver enzymes and serum uric acid.
Weighted prevalence or
odds ratio (OR) (95%
confidence interval)
Study cohort Without
hyperuricemiaa
With
hyperuricemiaa
Unweighted, n n Z 5370 n Z 4489 n Z 881
AST (U/L) > 37 (M), >31 (W) 3.9% 3.0% 8.9% <0.001
ALT (U/L) > 40 (M), >31 (W) 5.5% 4.7% 9.6% <0.001
Abnormal liver enzymesb 6.6% 5.4% 12.6% <0.001
Abnormal liver enzymes:
Unadjusted OR 1 2.5 (1.7e3.8) <0.001
Age- and sex-adjusted OR 1 2.5 (1.7e3.8) <0.001
Multivariable-adjusted ORc 1 1.8 (1.1e2.7) 0.01
Data are presented by incorporating sample weights and adjusted for clusters and strata of the complex sample design of the Third
National Health and Nutrition Examination Survey.
ALT Z alanine aminotransferase; AST Z aspartate aminotransferase; M Z men; W Z women.
a Hyperuricemia: >7 mg/dL in men; >5.7 mg/dL in women.
b Abnormal liver enzymes were defined as elevated AST and/or ALT without excessive alcohol consumption, hepatitis B or C virus
infections, or serum transferrin saturation >50%.
c Adjusted for age, sex, race/ethnicity, alcohol consumption, body mass index, (systolic) blood pressure, fasting glucose, high-density
lipoprotein cholesterol and triglycerides.
Serum uric acid and NAFLD 319phosphate depletion [adenosine triphosphate (ATP) deple-
tion], which increases uric acid production.18,19 Some
studies have shown that hepatic ATP depletion also leads to
arrest in protein synthesis and produces inflammatory and
pro-oxidative changes.20,21 One recent review article by
Lim et al. postulates that excessive dietary fructose
consumption may contribute to the development of
NAFLD.4 Additionally, increased SUA itself may also produce
pro-inflammatory and pro-oxidative effects.22 Ruggiero
et al. showed a positive and significant relationship
between SUA and many inflammatory markers in Italian
men.23 Thus ATP depletion and SUA itself may lead to
hepatocellular injury (elevated liver enzymes) and
progression of NAFLD. Indeed, some studies have showed
that SUA levels are associated with the progression of
chronic liver diseases such as NAFLD and NASH12 and
hyperuricemia is independently associated with the
severity of liver damage among NAFLD patients.24 However,
in our study we did not find an association between NASH
and SUA level among patients with NAFLD. Maybe this is
because of the small number of NASH participants
(n Z 231). In addition, one prospective study of SUA and
NAFLD has been reported. Xu et al in China followed 6890
men and women without NAFLD for 3 years and found
a higher incidence of NAFLD in those with higher baseline
SUA levels.25
Our study has several limitations. First, given the cross-
sectional design, we are unable to determine causality.
Second, the diagnosis of NAFLD by ultrasound is relatively
insensitive as compared to that by biopsy26 although the
recent study showed that ultrasound allows for reliable and
accurate in the detection of moderate-to-severe fatty liver
compared to histology.27 Thus, we are unable to determine
the association between SUA and lesser degrees of stea-
tosis. Third, we did not consider other potential con-
founding factors on SUA level such as diet patterns. Fourth,
it should be a weakness to use in this study only around 40%
of the cohort. Finally, individuals with more severe NAFLD,especially if hospitalized or in a nursing home, would have
been unlikely to take part in NHANES, thus our associations
are likely limited to moderate NAFLD, and not end-stage
liver disease. Nevertheless, our study was performed
using a nationally representative sample of US women and
men, allowing for population-based estimates that can be
generalized to the noninstitutionalized US population. In
addition, given the large sample size and design of NHANES,
we were able to control for multiple confounders, including
all of the components of the MetS, establishing an associ-
ation independent of these factors.
In conclusion, we found a significant association
between SUA levels and NAFLD among the US population,
independent of multiple metabolic risk factors. More
prospective studies are needed to clarify the temporality of
the association. If hyperuricemia proves to be in the causal
pathway for NAFLD, then prevention or treatment of
hyperuricemia may reduce the risk of development or
progression of NAFLD. If hyperuricemia proves to be
a consequence of NAFLD, then hyperuricemia could serve
as a trigger for physicians to screen for NAFLD and liver
disease, since it can identify someone at high risk for NAFLD
independent of other currently acceptable factors.
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